Clinical Trials Logo

Ameloblastoma clinical trials

View clinical trials related to Ameloblastoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04987515 Completed - Clinical trials for the Recurrence of the Tumor

Clinical Evaluation of Fenestration Decompression Combined With Secondary Curettage for Ameloblastoma of the Jaw: Retrospective Radiographic Analysis

Start date: January 1, 2010
Phase:
Study type: Observational

Objectives: To investigate the outcomes of fenestration decompression combined with secondary curettage (FDSC) in the surgical treatment of jaw ameloblastoma. Methods: Medical records of patients diagnosed as multicystic ameloblastoma (MA) or unicystic ameloblastoma (UA) by routine pathology were collected from January 2010 to December 2017 in Ninth People's Hospital, Shanghai JiaoTong University Medical College. Patients were divided into two groups based on the management regimen: FDSC group, and local curettage (LC) group. Patients were followed up for 3-8 years, using panoramic radiography to measure the change of the area of the cystic cavity involved in ameloblastoma and the recurrence or malignant transformation of the tumor in both groups. A total of 233 eligible patients were selected for provisional screening, including 145 patients with MA, and 88 patients with UA.

NCT ID: NCT02367859 Completed - BRAF Gene Mutation Clinical Trials

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Start date: July 17, 2017
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.